GeneCast Biotechnology is dedicated to improving cancer treatment through precision cancer diagnostics and companion diagnostics.
Genecast offers DNA testing of tumors and gene-based medicine guidance. The company claims expertise in lung, colon, liver and breast cancers. Genecast plans to use the proceeds for further research and clinical trials, as well as expanding distribution channels.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 26, 2020 | Series E | — | 7 | China Structural Reform Fund | — | Detail |
Oct 30, 2019 | Series D | ¥300M | 4 | CICC | — | Detail |
Feb 27, 2018 | Series C | $33M | 4 | Loyal Valley Capital Matrix Partners China | — | Detail |
Sep 18, 2017 | Seed | — | 1 | — | — | Detail |
Feb 10, 2017 | Series B | $18M | 1 | Tsinghua Holdings | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
China Structural Reform Fund | Yes | Series E |
CICC | Yes | Series D |
Loyal Valley Capital | Yes | Series C |
Tsinghua Holdings | Yes | Series B |
China Capital Investment Group | — | Series E |
China Renaissance | — | Series E |
Hillhouse Capital Group | — | Series E |
Jianxin Capital | — | Series E |
Matrix Partners China | — | Series E |
Taikang Asset | — | Series E |